Breakthrough in the development of a diagnostic test for oesophageal cancer

February 8, 2012

A team of scientists, led by the University of Liverpool, has made a major advance in the development of a diagnostic test for oesophageal cancer. The findings, achieved at STFC's ALICE accelerator facility, will lead to major improvements in the diagnosis, treatment and prognosis of the disease.

Oesophageal cancer is the ninth most common cancer in the world and around 8000 people are diagnosed every year in the UK. It is an extremely difficult cancer to diagnose and is highly aggressive. Patients often present when the is at an advanced stage, when surgical removal is no longer possible.

The aim of the research is to develop a by imaging tissue obtained by from patients with a precursor condition called Barrett's Oesophagus. Patients with Barrett's Oesophagus are more at risk of developing this form of cancer and are regularly monitored to detect changes in their condition. If are detected in these patients, they can undergo potentially without the need for because the tumours have been detected at a much earlier stage.

By using a unique and extremely intense source of (the InfraRed ) at the pioneering ALICE accelerator at STFC's Daresbury Laboratory, Professor Peter Weightman and his team have been able to image and carry out a blind study of historical endoscopic samples from patients with Barrett's Oesophagus and, by detecting changes that took place in the samples, have developed a diagnostic test for the disease.

Minister for Universities and Science David Willetts said: “It’s incredibly impressive that the UK’s leading physics research can bring benefits for our health and wellbeing, as well as telling us more about the world around us. This work has the potential to save lives and revolutionise the diagnosis and treatment of oesophageal cancer. It also demonstrates the value of the Government’s investment in the Daresbury Laboratory. I wish the researchers well in taking these findings through to clinical use.”

Professor Weightman of University of Liverpool said: "Early diagnosis is the most important factor for improving the prognosis for patients with oesophageal cancer. But it is extremely hard to diagnose accurately - a false negative test can be fatal, whereas a false positive means unnecessary major surgery."

Project collaborator, Professor Mark Pritchard, Consultant Gastroenterologist at Royal Liverpool University Hospital said: "Unfortunately, many patients with have inoperable cancers by the time of presentation, and even when surgery is performed it can often be unsuccessful. There is a real, pressing clinical need to develop new technologies which can detect early changes that occur within individual cells prior to cancer development. Using ALICE, Professor Weightman has been able to detect such cellular changes. This technology may have similar applications in other types of cancer which have a well established premalignant stage."

Professor Weightman added: "Eventually we hope to develop a diagnostic test that can be used in an endoscope. The most promising approach may be to develop a test using the intense terahertz light also generated by ALICE. ALICE is Europe's most intense band source of terahertz light and the only one in the world equipped with a tissue culture facility for research on cancer. This would lead to much cheaper and more efficient diagnosis of the disease. However this development is some way off."

STFC's Professor Susan Smith, responsible for ALICE, said: "It is fantastic news that, through ALICE, we now have an improved technology that could lead to significant advances in the treatment of cancer. With ALICE we have an opportunity to look at cells in a way that has not been done before. It is particularly exciting that these experiments are now pointing towards an accurate diagnostic test that could change the lives of thousands of patients and we look forward to continuing to work with Professor Weightman as he takes this invaluable research to the next level."

ALICE, at STFC's Daresbury Laboratory in Cheshire, is an R&D prototype for the next generation of particle accelerators and is the first of its kind in Europe. It is based upon a new mode of operation, known as energy recovery, where the energy used to create its high energy beam is captured and re-used after each circuit of the accelerator, so less power is required making it cheaper to run. Electrons are sent round the accelerator at 99.99% of the speed of light and 99.9% of the power at the final accelerator stage is recovered and re-used.

Explore further: 'Sponge on a string' trial launched to try and prevent deadly oesophageal cancer

Related Stories

'Sponge on a string' trial launched to try and prevent deadly oesophageal cancer

October 14, 2011
(Medical Xpress) -- Cancer Research UK has launched a large multi-centre trial to test a new device for detecting Barrett’s oesophagus – a condition that puts sufferers at increased risk of developing cancer of ...

Barrett's patients who smoke twice as likely to develop oesophageal cancer

January 30, 2012
Smoking doubles the risk of developing oesophageal cancer in people with Barrett's Oesophagus, according to scientists at Queen's University Belfast and the Northern Ireland Cancer Registry.

Fluorescent dye pinpoints tiniest signs of oesophageal cancer

January 16, 2012
(Medical Xpress) -- A fluorescent dye that can be sprayed onto the oesophagus – the food pipe – could be used to detect oesophageal cancer earlier and spare patients unnecessary treatment, according to research ...

Researchers use sugar to halt esophageal cancer in its tracks

January 15, 2012
Scientists working at the Medical Research Council have identified changes in the patterns of sugar molecules that line pre-cancerous cells in the esophagus, a condition called Barrett's dysplasia, making it much easier to ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.